Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma

Hepatology Research

Volumn 44, Issue 13, 2014, Pages 1329-1338

  Jo, Masayasu ^a,b   Yasui, Kohichiroh ^a   Kirishima, Toshihiko ^c   Shima, Toshihide ^d   Niimi, Toshihisa ^e   Katayama, Takayuki ^a,e   Mori, Takahiro ^f   Funaki, Jun ^g   Sumida, Yoshio ^a,h   Fujii, Hideki ⁱ   Takami, Shiro ^j   Kimura, Hiroyuki ^k   Mitsumoto, Yasuhide ^f,i   Minami, Masahito ^a   Yamaguchi, Kanji ^a   Yoshinami, Naomi ^c   Mizuno, Masayuki ^d   Sendo, Rei ^d,e   Tanaka, Saiyu ^h   Shintani, Hiroyuki ^c   Kagawa, Keizo ^e   Okanoue, Takeshi ^d   Itoh, Yoshito ^a   more..

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KYOTO CITY HOSPITAL   (Japan)

^d Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

^e Fukuchiyama City Hospital   (Japan)

^f WEST JAPAN RAILWAY COMPANY   (Japan)

^g Center for Cerebrovascular Disease   (Japan)

^h Nara City Hospital   (Japan)

ⁱ Department of Internal Medicine Aiseikai Yamashina Hospital ^*  (Japan)

^j Otsu Municipal Hospital   (Japan)

^k KYOTO FIRST RED CROSS HOSPITAL   (Japan)

more..

Author keywords

Elderly patient; Hepatocellular carcinoma; Sorafenib

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN HEMORRHAGE; BRAIN INFARCTION; CANCER CHEMOTHERAPY; CANCER STAGING; CHILD PUGH SCORE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; ERYTHEMA MULTIFORME; EXOPHTHALMOS; FATIGUE; FEMALE; HAND FOOT SKIN REACTION; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPENSITY SCORE; RUPTURE OF ESOPHAGEAL VARICE; SEPSIS; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR INVASION; VERY ELDERLY;

EID: 84927575972     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12308     Document Type: Article

References (15)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
2. Ikai I, Arii S, Okazaki M etal. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2007; 37: 676-691.
3. Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update. Hepatol Res 2013; 43: 147-154.
4. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
5. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
6. Bruix J, Sherman M, Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
7. Oken MM, Creech RH, Tormey DC etal. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
8. Pugh RN, Murray-Lyon IM, Dawson JL etal. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
9. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
10. Connors AF Jr, Speroff T, Dawson NV etal. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA 1996; 276: 889-897.
11. The Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 3rd English edn. Tokyo: Kanehara & Co., Ltd., 2010.
12. Morimoto M, Numata K, Kondo M etal. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res 2011; 41: 296-302.
13. Montella L, Addeo R, Cennamo G etal. Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series. Oncology 2013; 84: 265-272.
14. Di Costanzo GG, Tortora R, De Luca M etal. Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. Med Oncol 2013; 30: 446.
15. Wong H, Tang YF, Yao TJ etal. The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). Oncologist 2011; 16: 1721-1728.